Ken Griffin’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Ken Griffin’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-805	Closed	-$30K	–	14436
2022 Q1	$30K	Buy	+805	New	+$27.8K	﹤0.01%	13113
2021 Q4	–	Sell	-900	Closed	-$65K	–	15032
2021 Q3	$65K	Sell	900 -410	-31%	-$31.4K	﹤0.01%	13214
2021 Q2	$126K	Buy	1,310 +805	+159%	+$88.9K	﹤0.01%	12700
2021 Q1	$75K	Buy	+505	New	+$91.5K	﹤0.01%	12694
2016 Q1	–	Sell	-16	Closed	-$38K	–	8219
2015 Q4	$38K	Buy	16 +3	+23%	+$4.61K	﹤0.01%	7513
2015 Q3	$14K	Buy	13 +3	+30%	+$3.48K	﹤0.01%	8357
2015 Q2	$10K	Sell	10 -21	-68%	-$22.6K	﹤0.01%	8408
2015 Q1	$31K	Buy	+31	New	+$102K	﹤0.01%	7681
2014 Q4	–	Sell	-17	Closed	-$50K	–	8793
2014 Q3	$50K	Sell	17 -143	-89%	-$473K	﹤0.01%	6906
2014 Q2	$609K	Buy	+160	New	+$602K	﹤0.01%	4138

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

Ken Griffin's NBSE Position: Q4 2022 in Review

Ken Griffin sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 1,140 shares — an estimated $9K sold.

Ken Griffin first reported a position in NBSE in Q2 2014 and held it in 23 quarters. The position peaked at $293K in Q4 2020. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

Ken Griffin reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Ken Griffin sold 1,140 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
Ken Griffin first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 23 quarters.
Ken Griffin's NeuBase Therapeutics, Inc. Common Stock position peaked at $293K in Q4 2020.
34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.